These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 12113078)

  • 21. Progression-free survival remains debatable endpoint in cancer trials.
    Tuma R
    J Natl Cancer Inst; 2009 Nov; 101(21):1439-41. PubMed ID: 19828873
    [No Abstract]   [Full Text] [Related]  

  • 22. [New treatment of metastatic renal cancer. The Danish Society of Clinical Oncology].
    Sengeløv L; Geertsen PF;
    Ugeskr Laeger; 2007 Mar; 169(12):1117. PubMed ID: 17394828
    [No Abstract]   [Full Text] [Related]  

  • 23. Some ethical issues in phase II trials in acute leukemia.
    Thall PF; Estey EH; Markman M
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):95. PubMed ID: 16739255
    [No Abstract]   [Full Text] [Related]  

  • 24. Outcomes and prognosis in advanced renal cell carcinoma.
    Galsky MD; Vogelzang NJ
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):839-45. PubMed ID: 17555394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Technology evaluation: GEM-231, Hybridon.
    Yeung PK
    Curr Opin Mol Ther; 2003 Jun; 5(3):315-20. PubMed ID: 12870443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimising the design of phase II oncology trials: the importance of randomisation.
    Ratain MJ; Sargent DJ
    Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorafenib for the treatment of advanced renal cell carcinoma.
    Kane RC; Farrell AT; Saber H; Tang S; Williams G; Jee JM; Liang C; Booth B; Chidambaram N; Morse D; Sridhara R; Garvey P; Justice R; Pazdur R
    Clin Cancer Res; 2006 Dec; 12(24):7271-8. PubMed ID: 17189398
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Creeping phase II-ism and the medical pharmaceutical complex: weapons of mass distraction in the war against lung cancer.
    Turrisi AT
    J Clin Oncol; 2005 Aug; 23(22):4827-9. PubMed ID: 15939926
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of growth inhibitory agents in urological and other malignancies.
    Stadler WM
    BJU Int; 2006 Sep; 98(3):497-502. PubMed ID: 16827906
    [No Abstract]   [Full Text] [Related]  

  • 30. Newer phase II trial designs gaining ground.
    Benowitz S
    J Natl Cancer Inst; 2007 Oct; 99(19):1428-9. PubMed ID: 17895467
    [No Abstract]   [Full Text] [Related]  

  • 31. Technology evaluation: CpG-7909, Coley.
    Paul S
    Curr Opin Mol Ther; 2003 Oct; 5(5):553-9. PubMed ID: 14601526
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Taking stock of targeted therapy in cancer: rational expectations or irrational exuberance?
    Edelman MJ
    Expert Rev Anticancer Ther; 2003 Apr; 3(2):127-9. PubMed ID: 12722869
    [No Abstract]   [Full Text] [Related]  

  • 33. Molecule of the month. Sorafenib.
    Drug News Perspect; 2006 Mar; 19(2):119. PubMed ID: 16628266
    [No Abstract]   [Full Text] [Related]  

  • 34. Sorafenib: delivering a targeted drug to the right targets.
    Flaherty KT
    Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS.
    Estey EH
    Ann Hematol; 2004; 83 Suppl 1():S94-6. PubMed ID: 15124692
    [No Abstract]   [Full Text] [Related]  

  • 36. Optimizing randomized phase II trials assessing tumor progression.
    Stone A; Wheeler C; Carroll K; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):146-52. PubMed ID: 16807129
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved confidence intervals for a binomial parameter following a group sequential phase II clinical trial.
    Chang MN
    Stat Med; 2004 Sep; 23(18):2817-26. PubMed ID: 15344188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The sensitivity of human kidney cancer in cultures to antitumor preparations].
    Terent'eva TG; Fomina IP; Navashin SM; Martochkina GA
    Vopr Onkol; 1971; 17(7):67-70. PubMed ID: 5002944
    [No Abstract]   [Full Text] [Related]  

  • 39. GlycoDesign expands phase II clinical trials for GD0039.
    Expert Rev Anticancer Ther; 2001 Dec; 1(4):507-8. PubMed ID: 12113078
    [No Abstract]   [Full Text] [Related]  

  • 40. Signal-transduction inhibitors in renal cell carcinoma.
    Vogelzang NJ; Sternberg CN
    BJU Int; 2007 May; 99(5 Pt B):1289-95. PubMed ID: 17441926
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.